Soojin Kim

Title: Soojin Kim: Innovator in Gene Therapy and Hepatotoxicity Evaluation

Introduction

Soojin Kim is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the fields of gene therapy and drug evaluation, holding a total of 11 patents. His innovative work focuses on minimizing recombination in gene therapy vectors and developing platforms for assessing liver toxicity.

Latest Patents

Soojin Kim's latest patents include a gene therapy vector designed to minimize recombination, which is a critical issue in the production and infection of retroviral vectors. This vector incorporates a cleaved MCMV promoter that ensures continuous expression of therapeutic genes without causing recombinations. Additionally, he has developed a microfabricated platform that mimics liver zonation, allowing for the evaluation of zone-specific hepatotoxicity. This platform is divided into three zones, enabling quantitative analysis of drug toxicity in liver tissues.

Career Highlights

Throughout his career, Soojin Kim has worked with notable companies such as LG Chem, Ltd and Articure, Inc. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.

Collaborations

Soojin Kim has collaborated with several professionals in his field, including Jeong-Ju Cho and Mikyung Chung, who have contributed to his research endeavors.

Conclusion

Soojin Kim's work in gene therapy and hepatotoxicity evaluation showcases his commitment to advancing medical science. His innovative patents and collaborations highlight his significant impact on the field.